The Vendor Drug Program (VDP) temporarily removed the non-preferred status in the "Hypoglycemics, Insulins" drug class on April 1, 2020, in response to reported drug shortages for insulin products. VDP will reverse this change in status when there is sufficient availability in the market.
VDP made this determination after verifying the current availability of the preferred insulin products, as well as the non-preferred insulin products through multiple sources such as the American Society of Health System Pharmacists (ASHP), the Food and Drug Administration (FDA), manufacturers, wholesalers, and pharmacies in various regions around Texas.
Beginning September 18, 2020, the formulary will reflect the Preferred /Drug List (PDL) status changes for all non-preferred insulin products. VDP will restore the non-preferred status on the drugs listed on the following VDP webpage when there is sufficient product availability:
Contact firstname.lastname@example.org with comments or any questions.